Navigation Links
Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
Date:5/6/2013

NESS ZIONA, Israel, May 6, 2013 /PRNewswire/ --

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for a long acting depot formulation of glatiramer acetate. The formulation is under development as a once-a-month treatment for Multiple Sclerosis (MS). The existing glatiramer acetate dosage form on the market today requires daily administrations (by injection).

US Patent number 8,377,885 B2 is titled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof. The glatiramer acetate depot formulation described therein is to be injected once-a-month under the skin or into a muscle for a prolonged release of the therapeutic agent.

"It is a bright day both for MS patients and Mapi Pharma. Today's news strengthens Mapi's patent position, supports its business plan and advances the company one step closer to bringing MS patients an improved drug to be administered once-a-month," said Mapi Pharma President & CEO Mr. Ehud Marom .

MS is a chronic, often disabling disease that attacks the central nervous system. Symptoms include numbness in the limbs, paralysis and loss of vision. Symptoms are unpredictable and differ from one person to another. The global market for MS pharmaceuticals is estimated to be approximately US $10 billion.

About Mapi-Pharma

Mapi Pharma (Mapi) is an international pharmaceutical company specializing in complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, high development barrier generics and novel finished dosage forms based on selected drug delivery systems. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs and its ability to foster local cooperation and enduring relationships in all of the countries in which it is present. Mapi is dedicated to providing generic and innovative intermediates & APIs as well as developing finished dosage forms - either to Mapi's internal API program, as a vertically integrated company, or generic, to other leading brands. Mapi is headquartered in Israel.  It has R&D facilities in Israel, China and Germany and is currently building an API manufacturing site in Neot Hovav, Israel's designated chemical park. The company has a strong IP position, filing more than 20 patent applications for APIs and formulations in less than three years of operation. For more information: http://www.mapi-pharma.com.

Press Contact:
Marjie Hadad
Media Liaison
Mapi Pharma
marjie@mapi-pharma.com
+972-54-536-5220


'/>"/>
SOURCE Mapi Pharma Ltd. (Mapi)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
2. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
3. Valeant Pharmaceuticals Provides Efinconazole Update
4. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
5. Cumberland Pharmaceuticals Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
7. Webcast Alert: Isis Pharmaceuticals First Quarter 2013 Financial Results Conference Call
8. 2013 Pharmaceutical Drug Naming Trends
9. SynteractHCR Addressing Successful Ways to Approach Sponsor and CRO Collaboration at May Pharmaceutical Events in US and Europe
10. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
11. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016   ... that Nationwide Children,s Hospital signed a ... and accelerate the development of new cures. ... organizations representing over 57 million patients globally, biopharmaceutical ... working together to improve protocol design, site selection, ...
(Date:12/8/2016)... True Health Diagnostics today announced a ... and management expertise to hospital systems throughout ... doctors and patients to benefit from state-of-the-art biomarker ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... to contain costs, have struggled to keep up ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):